08:00 - 11:00

Interventional Pneumology CHEST Experience - Part 1

Learn new skills and refresh your knowledge through this hands-on, interactive course led by experts in bronchoscopy and procedure-related training. Attend and acquire essential and advanced diagnostic bronchoscopy techniques, including:

- Conventional and EBUS-guided TBNA
- Anatomy identification of airway nodes
- Management of airway bleeding
- Management of a pneumothorax

Attend to experience:

- Hands-on training, including techniques for conventional TBNA, step-by-step approach to EBUS-guided TBNA, endobronchial blockers placement for massive hemoptysis, management of pneumothorax, mediastinal anatomy on EBUS, Anatomy identification and guidance using simulated CT scanning and high-fidelity simulators.
- Cognitive and skills testing on issues essential to conventional and EBUS-TBNA, EBUS scope and processor knobology, managing a pneumothorax, managing airway bleeding. Pre- and post-course cognitive knowledge testing, as well as testing of procedural skills during breakout sessions, offers a personalized, learner-centric approach to teaching.
- Case-based, interactive session to encourage honest, individual responses. Group responses will allow faculty to focus on both group and individual learning needs. Only interactive lectures are used in this course, as they lead to better retention, better knowledge gain, and learner’s satisfaction. Target Audience

Physicians and health-care professionals from pulmonary and critical care medicine, intensive care medicine, and thoracic surgery are encouraged to attend.

K. Affolter (Olten, CH)
P. Chhajed (Mumbai, IN)
P. Grendelmeier (Basel, CH)
T. Hess (Winterthur, CH)
L. Kern (St. Gallen, CH)
A. Lovis (Lausanne, CH)
J. Plojoux (Geneva, CH)
A. Rosell (Barcelona, ES)
O. Rickman (Nashville, US)
S. Levine (San Antonio, US)
C. Lamb (Burlington, US)
08:00 - 11:00

**Interventional Pneumology CHEST Experience - Part 2**

Learn new skills and refresh your knowledge through this hands-on, interactive course led by experts in bronchoscopy and procedure-related training. Attend and acquire essential and advanced diagnostic bronchoscopy techniques, including:

- Conventional and EBUS-guided TBNA
- Anatomy identification of airway nodes
- Management of airway bleeding
- Management of a pneumothorax

Attend to experience:

- Hands-on training, including techniques for conventional TBNA, step-by-step approach to EBUS-guided TBNA, endobronchial blockers placement for massive hemoptysis, management of pneumothorax, mediastinal anatomy on EBUS, Anatomy identification and guidance using simulated CT scanning and high-fidelity simulators.
- Cognitive and skills testing on issues essential to conventional and EBUS-TBNA, EBUS scope and processor knobology, managing a pneumothorax, managing airway bleeding.

Pre- and post-course cognitive knowledge testing, as well as testing of procedural skills during breakout sessions, offers a personalized, learner-centric approach to teaching.

Case-based, interactive session to encourage honest, individual responses. Group responses will allow faculty to focus on both group and individual learning needs. Only interactive lectures are used in this course, as they lead to better retention, better knowledge gain, and learner's satisfaction.

**Target Audience**

Physicians and health-care professionals from pulmonary and critical care medicine, intensive care medicine, and thoracic surgery are encouraged to attend.

K. Affolter (Olten, CH)
P. Chhajed (Mumbai, IN)
T. Hess (Winterthur, CH)
P. Grendelmeier (Basel, CH)
L. Kern (St. Gallen, CH)
A. Lovis (Lausanne, CH)
J. Plojoux (Geneva, CH)
A. Rosell (Barcelona, ES)
O. Rickman (Nashville, US)
S. Levine (San Antonio, US)
C. Lamb (Burlington, US)
CheST Experience, Boston 1&2

08:00 - 11:00

Interventional Pneumology CHEST Experience - Part 3

Learn new skills and refresh your knowledge through this hands-on, interactive course led by experts in bronchoscopy and procedure-related training. Attend and acquire essential and advanced diagnostic bronchoscopy techniques, including:

- Conventional and EBUS-guided TBNA
- Anatomy identification of airway nodes
- Management of airway bleeding
- Management of a pneumothorax

Attend to experience:
- Hands-on training, including techniques for conventional TBNA, step-by-step approach to EBUS-guided TBNA, endobronchial blockers placement for massive hemoptysis, management of pneumothorax, mediastinal anatomy on EBUS, Anatomy identification and guidance using simulated CT scanning and high-fidelity simulators.
- Cognitive and skills testing on issues essential to conventional and EBUS-TBNA, EBUS scope and processor knobology, managing a pneumothorax, managing airway bleeding. Pre- and post-course cognitive knowledge testing, as well as testing of procedural skills during breakout sessions, offers a personalized, learner-centric approach to teaching.
- Case-based, interactive session to encourage honest, individual responses. Group responses will allow faculty to focus on both group and individual learning needs. Only interactive lectures are used in this course, as they lead to better retention, better knowledge gain, and learner's satisfaction.

Target Audience
Physicians and healthcare professionals from pulmonary and critical care medicine, intensive care medicine, and thoracic surgery are encouraged to attend.

K. Affolter (Olten, CH)
P. Chhajed (Mumbai, IN)
P. Grendelmeier (Basel, CH)
T. Hess (Winterthur, CH)
L. Kern (St. Gallen, CH)
A. Lovis (Lausanne, CH)
J. Plojoux (Geneva, CH)
A. Rosell (Barcelona, ES)
O. Rickman (Nashville, US)
S. Levine (San Antonio, US)
C. Lamb (Burlington, US)
Interventional Pneumology CHEST Experience - Part 4

Learn new skills and refresh your knowledge through this hands-on, interactive course led by experts in bronchoscopy and procedure-related training. Attend and acquire essential and advanced diagnostic bronchoscopy techniques, including:

- Conventional and EBUS-guided TBNA
- Anatomy identification of airway nodes
- Management of airway bleeding
- Management of a pneumothorax

Attend to experience:

- Hands-on training, including techniques for conventional TBNA, step-by-step approach to EBUS-guided TBNA, endobronchial blockers placement for massive hemoptysis, management of pneumothorax, mediastinal anatomy on EBUS, Anatomy identification and guidance using simulated CT scanning and high-fidelity simulators.
- Cognitive and skills testing on issues essential to conventional and EBUS-TBNA, EBUS scope and processor knobology, managing a pneumothorax, managing airway bleeding. Pre- and post-course cognitive knowledge testing, as well as testing of procedural skills during breakout sessions, offers a personalized, learner-centric approach to teaching.
- Case-based, interactive session to encourage honest, individual responses. Group responses will allow faculty to focus on both group and individual learning needs. Only interactive lectures are used in this course, as they lead to better retention, better knowledge gain, and learner's satisfaction.

Target Audience: Physicians and health-care professionals from pulmonary and critical care medicine, intensive care medicine, and thoracic surgery are encouraged to attend.

K. Affolter (Olten, CH)
P. Chhajed (Mumbai, IN)
P. Grendelmeier (Basel, CH)
T. Hess (Winterthur, CH)
L. Kern (St. Gallen, CH)
A. Lovis (Lausanne, CH)
J. Plojoux (Geneva, CH)
A. Rosell (Barcelona, ES)
O. Rickman (Nashville, US)
S. Levine (San Antonio, US)
C. Lamb (Burlington, US)

08:15 - 09:15  5  Bodyplethysmography

Background and purpose, theory, equipment and measurement technique, measurement of Resistance, FRC, ERV and VC using body plethysmography and spirometry, quality control, reference values. Measurement of a proband. Participation is limited to 12 delegates.

J. Leuppi (Liestal, CH)
Scientific Programme

08:15 - 09:15  
**Hands-on-Workshop 3: CPET**  
Background and purpose, theory, equipment and measurement technique, measurement and calculations of values, quality control, reference values and 9-field-panel of Wasserman. Measurement of a healthy proband. Participation is limited to 12 delegates.  
P.-O. Bridevaux (Hôpital du Valais, Sion, CH)

08:15 - 09:15  CPET

09:30 - 10:45  
**Plenary Session 1: Welcome and Keynote Lecture**

09:30 - 10:00  
**Official Opening and Welcome**  
D. Stolz (Basel, CH)  
M. Brutsche (St. Gallen, CH)  
G. Silvestri (Charleston, US)

10:00 - 10:45  
**Keynote Lecture 1: Impact of big data on global health and clinical decision making**  
B. Ustun (Geneva, CH)

11:00 - 12:15  
**Session 1: Diagnosis and treating ILD**  
This session will be recorded and made available as webcast on the congress website and on the Novartis website “Vivinda TV” after the congress.

11:00 - 11:18  
**Cryobiopsy for the diagnosis of ILD**  
V. Poletti (Foli, IT)

11:18 - 11:36  
**Unclassifiable ILD**  
A. Wells (London, GB)

11:36 - 11:54  
**Therapy of IPF between past and future**  
L. Nicod (Lausanne, CH)

11:54 - 12:12  
**Antifibrotic therapy in non-IPF lung diseases**  
F. Martinez (New York, US)
### Parallel Session, Singapore

**11:00 - 12:15**

**Session 2: Cough causes and treatment strategies**

<table>
<thead>
<tr>
<th>Time</th>
<th>Number</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 - 11:18</td>
<td>14</td>
<td>Upper respiratory tract and cough</td>
<td>L. McGarvey (Belfast, IE)</td>
</tr>
<tr>
<td>11:18 - 11:36</td>
<td>15</td>
<td>GERD and laryngeal-pharyngeal reflux</td>
<td>J. Smith (Manchester, GB)</td>
</tr>
<tr>
<td>11:36 - 11:54</td>
<td>16</td>
<td>Laryngeal dysfunction</td>
<td>J. Hull (London, GB)</td>
</tr>
<tr>
<td>11:54 - 12:12</td>
<td>17</td>
<td>Managing the chronic unexplained cough</td>
<td>R. Irwin (Worcester, US)</td>
</tr>
</tbody>
</table>

### Parallel Session, Sydney

**11:00 - 12:15**

**Session 3: CF and non-CF bronchiectasis**

<table>
<thead>
<tr>
<th>Time</th>
<th>Number</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 - 11:18</td>
<td>18</td>
<td>Microbiome in lung disease</td>
<td>M. Hilty (Bern, CH)</td>
</tr>
<tr>
<td>11:18 - 11:36</td>
<td>19</td>
<td>Fungi in CF and non-CF bronchiectasis</td>
<td>K. Jahn (Basel, CH)</td>
</tr>
<tr>
<td>11:36 - 11:54</td>
<td>20</td>
<td>Lung function and multiple-breath washout</td>
<td>K. Ramsey (Chapel Hill, US)</td>
</tr>
<tr>
<td>11:54 - 12:12</td>
<td>21</td>
<td>Modifying disease in cystic fibrosis</td>
<td>P. Latzin (Bern, CH)</td>
</tr>
</tbody>
</table>

### Parallel Session, Samarkand

**11:00 - 12:15**

**Session 4: Personalised treatments for severe asthma**

This session will be recorded and made available as webcast on the congress website and on the Novartis website “Vivinda TV” after the congress.

<table>
<thead>
<tr>
<th>Time</th>
<th>Number</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 - 11:18</td>
<td>22</td>
<td>Precision medicine in severe asthma</td>
<td>F. Blasi (Milan, IT)</td>
</tr>
<tr>
<td>11:18 - 11:36</td>
<td>23</td>
<td>Asthma phenotypes</td>
<td>F. Chung (London, GB)</td>
</tr>
</tbody>
</table>
Scientific Programme

11:36 - 11:54  24  Biologics for severe asthma  
R. Louis (Liege, BE)

11:54 - 12:12  25  Thermoplasty for severe asthma  
D. Stolz (Basel, CH)

Satellite Symposium, Montreal

12:45 - 13:45  Satellite Symposium 1 - From latest evidences in COPD treatment to the future of anti-IgE in asthma treatment  
Supported by Novartis  
M. Tamm (Basel, CH)

12:45 - 12:50  26a  Introduction Chair  
M. Tamm (Basel, CH)

12:50 - 13:10  26  LABA/LAMA: from evidences to practical implementation  
K.-M. Beeh (Wiesbaden, DE)

13:10 - 13:30  27  The future of anti-IgE for the treatment of Asthma  
A. Menzies-Gow (Royal Brompton Hospital, London, GB)

13:30 - 13:45  28  Podium discussion  
M. Tamm (Basel, CH)  
K.-M. Beeh (Wiesbaden, DE)  
A. Menzies-Gow (Royal Brompton Hospital, London, GB)  
M. Kohler (Zurich, CH)

Satellite Symposium, Sydney

12:45 - 13:45  Satellite Symposium 2 - COPD in the trap: can we do better in deflating the captured air?  
Supported by PneumRx / Boehringer Ingelheim  
A. Valipour (Vienna, AT)

12:45 - 13:15  32  Wisdom and more: the dawn of LAMA/LABA in COPD treatment  
A. Valipour (Vienna, AT)

13:15 - 13:35  33  Interventional treatment options for COPD and emphysema  
D. Franzen (Zurich, CH)

13:35 - 13:45  34  Swiss experience on emphysema treatment with coils: EU registry data  
J. Plojoux (Geneva, CH)
Hands-on Workshop 10: Indication and application training of the PleurX®-catheter system

Dyspnea due to recurrent pleural effusion is one of the most frightening symptoms for palliative care patients. The PleurX®-catheter provides a new therapeutically option to achieve a rapid improvement of dyspnea in rest and during exertions, to reach a higher level of quality of life and from time to time a sufficient pleurodesis could be achieved. In this workshop we offer hands on training in insertion/application of the PleurX® Catheter using a thorax skin model. Additionally, you get detailed information about the home management using the intermittent drainage system and information regarding the follow up service.

K. Jahn (Basel, CH)
R. Marti (Neuhausen am Rheinfall, CH)

Hands-on Workshop 5: Endoscopic lung volume reduction with valves

non-CME accredited company supported hands-on workshop by PulmonX The workshop is designed to allow participants to gain practical skills in the placement of endobronchial valves in pig lung models. Besides, attendants will learn how to select the right patients by identifying collateral ventilation with the StratX software and the Chartis Assessment tool. Participation is limited to 12 delegates.

K. Klooster (Groningen, NL)

Hands-on Workshop 6: EBUS & peripheral procedures - Enlarge your diagnostic area

non-CME accredited company supported hands-on workshop by Olympus Participation is limited to 12 delegates

K.-J. Franke (Hagen, DE)
13:30 - 14:30  **Hands-on-Workshop 4: Physiotherapy in lung diseases**

Learn about physiotherapy techniques and assessments used in patients with lung diseases. This includes pulmonary rehabilitation in COPD, sputum mobilisation in Cystic Fibrosis, breathing techniques, such as pursed lip breathing in Asthma and body positioning for easier breathing. The Workshop is led by experienced physiotherapist. Attend to experience:

- Hands-on experience in using various Positiv Expiratory Pressure (PEP)-Systems such as Flutter VRP1, Acapella, Pari PEP or RC-Cornet.
- Learn about endurance and resistance training in pulmonary rehabilitation based on the latest research findings.
- Try out a sit-to-stand test as an alternative assessment to a 6 MWT

Target Audience: Physicians and health-care professionals from pulmonary medicine are encouraged to attend. Participation is limited to 12 delegates.

J. Schmidt Leuenberger (Bern, CH)
G. Büsching (Barmelweid, CH)
F. Vermeulen (Geneva, CH)

13:30 - 14:30  **Hands-on-Workshop 2: N2 washout method**

Short theoretical background and purpose of the multiple-breath washout (MBW) measurement technique. Explanation of the measurement of functional residual capacity (FRC) and lung clearance index (LCI) using two commercially available devices (EcoMedics and ndd) Hands-on calibration and measurement of a person including quality control of the measurement. Each participant will be able to ask specific questions as several experts will be available. Participation is limited to 12 delegates.

K. Ramsey (Chapel Hill, US)
S. Nyillas (Bern, CH)
P. Anagnostopoulou (Bern, CH)

13:30 - 14:30  **Hands-on-Workshop 3: CPET**

Background and purpose, theory, equipment and measurement technique, measurement and calculations of values, quality control, reference values and 9-field-panel of Wasserman. Measurement of a healthy proband. Participation is limited to 12 delegates.

J. Pichler Hefti (Inselspital, University Hospital Bern, Bern, CH)
### Parallel Session, Montreal

**14:00 - 15:15**

**Session 6: Optimised treatments for respiratory infections**

This session will be recorded and made available as webcast on the congress website and on the Novartis website “Vivinda TV” after the congress.

- **S. Aliberti** (Milan, IT)
- **M. Tamm** (Basel, CH)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 - 14:18</td>
<td>Severe community acquired pneumonia: mono or dual therapy?</td>
<td>W. Boersma (Alkmaar, NL)</td>
</tr>
<tr>
<td>14:18 - 14:36</td>
<td>Viral pneumonia: something to think about</td>
<td>M. van der Eerden (Rotterdam, NL)</td>
</tr>
<tr>
<td>14:36 - 14:54</td>
<td>Steroid in pneumonia: yes or no?</td>
<td>G. Li Bassi (Barcelona, ES)</td>
</tr>
<tr>
<td>14:54 - 15:12</td>
<td>Hospital acquired pneumonia</td>
<td>F. Blasi (Milan, IT)</td>
</tr>
</tbody>
</table>

### Parallel Session, Singapore

**14:00 - 15:15**

**Session 5: Taking lung imaging a step further**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 - 14:18</td>
<td>Progresses in imaging – MRI in lung disease</td>
<td>O. Bieri (Basel, CH)</td>
</tr>
<tr>
<td>14:18 - 14:36</td>
<td>Progresses in imaging – US in lung disease</td>
<td>G. Volpicelli (Turin, IT)</td>
</tr>
<tr>
<td>14:36 - 14:54</td>
<td>Progresses in imaging - virtual bronchoscopy</td>
<td>P. Brantner (Basel, CH)</td>
</tr>
<tr>
<td>14:54 - 15:04</td>
<td>COPD case finding and diagnosis</td>
<td>M. Han (Ann Arbor, US)</td>
</tr>
</tbody>
</table>

### Parallel Session, Sydney

**14:00 - 15:15**

**Session 7: Precision medicine for COPD**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 - 14:18</td>
<td>Accelerated ageing in COPD: news mechanisms and targets</td>
<td>P. Barnes (London, GB)</td>
</tr>
<tr>
<td>14:18 - 14:36</td>
<td>ACOS - phantom or reality?</td>
<td>J. Soriano (Mallorca, ES)</td>
</tr>
</tbody>
</table>
### Scientific Programme

**14:36 - 14:54** 51  
**Airway inflammation in COPD**  
M. Belvisi (London, GB)

**14:54 - 15:12** 52  
**Macrolides in COPD**  
F. Martinez (New York, US)

**Parallel Session, Samarkand**

**14:00 - 15:15**  
**Session 8: Detecting and treating lung cancer: 2017 update**  
J.-M. Fellrath (Neuchâtel, CH)  
R. Carbone (Genoa, IT)

**14:00 - 14:18** 53  
**Screening for lung cancer - where are we in 2017?**  
G. Silvestri (Charleston, US)

**14:18 - 14:36** 54  
**Immunotherapy in lung cancer - soon as first line therapy?**  
M. Früh (St. Gallen, CH)

**14:36 - 14:54** 55  
**Management of high risk patients: pro-stereotactic radiotherapy**  
A. Papachristofilou (Basel, CH)

**14:54 - 15:12** 56  
**Management of high risk patients: pro segmental resection**  
D. Lardinois (Basel, CH)

**Hands-on Course, Shanghai 1&2**

**15:00 - 16:00**  
**Hands-on-Workshop 7: Patient selection & valve therapy in emphysema**

*non-CME accredited company supported hands-on workshop by Olympus*  
*Participation is limited to 12 delegates*  
K.-J. Franke (Hagen, DE)

**15:00 - 16:00** 57  
**Patient selection & valve therapy in emphysema**

**Hands-on Course, Kairo 1&2**

**15:00 - 16:00**  
**Hands-on-Workshop 8: Hands-on practice with PneumRx coils for the endoscopic treatment of severe emphysema**

*non-CME accredited company supported hands-on workshop by PneumRx*  
*Participation is limited to 12 delegates*  
15:00 - 16:00 58  
**Hands-on practice with PneumRx coils for the endoscopic treatment of severe emphysema**
Scientific Programme

15:00 - 16:00  Hands-on Course, Shanghai 3

**Hands-on-Workshop 9: ASV- and BiPAP-AVAPS therapy using telemonitoring**

non-CME accredited company supported hands-on workshop by Philips Update in complex ASV (Auto-Servo-Ventilation) and BiPAP-AVAPS (Average Volume Assured Pressure Support) therapy in combination with telemonitoring. Assessment and decision with a focus on the therapy efficiency to reach the highest value of patients compliance. In this context you will become acquainted with an innovative wireless titration module which allows you to get all data in one final report. Participation is limited to 12 delegates

T. Kunze (Hamburg, DE)
D. Puoti (Zofingen, CH)

15:00 - 16:00  59

**ASV- and BiPAP-AVAPS therapy using telemonitoring**

Parallel Session, Montreal

15:45 - 16:45  Session 9: One step beyond: NIV and high-flow

J.-P. Janssens (Geneva University Hospitals, Geneva, CH)
N. Hart (London, GB)

15:45 - 16:05  60

**State of the art: NIV in COPD**

W. Windisch (Cologne, DE)

16:05 - 16:25  61

**CPAP for overlap syndrome?**

M. Drummond (Porto, PT)

16:25 - 16:45  62

**Is high-flow nasal therapy an alternative to NIV?**

W. Strobel (Basel, CH)

Parallel Session, Singapore

15:45 - 16:45  Session 10: Non-CF Bronchiectasis

R. Fischer (Bern, CH)
W. Boersma (Alkmaar, NL)

15:45 - 16:05  63

**When to suspect and what to examine**

C. Lambers (Vienna, AT)

16:05 - 16:25  64

**Bronchiectasis – a complication of COPD or a disease entity itself?**

T. Welte (Hannover, DE)

16:25 - 16:45  65

**Treating non-CF bronchiectasis**

S. Aliberti (Milan, IT)
Scientific Programme

Parallel Session, Sydney

15:45 - 16:45  
**Session 11: Nodule evaluation and endoscopic therapy of emphysema in 2017**

- P. Grendelmeier (Basel, CH)
- P. Chhajed (Mumbai, IN)

15:45 - 16:05  
Diagnostic and therapeutical approaches for peripheral nodules
- F. Herth (Heidelberg, DE)

16:05 - 16:25  
Endoscopic therapy of emphysema – enough evidence for routine clinical use?
- A. Valipour (Vienna, AT)

16:25 - 16:45  
Surgical therapy of emphysema – still evidence for routine clinical use?
- W. Weder (Zurich, CH)

Parallel Session, Samarkand

15:45 - 16:45  
**Session 12: Swiss Lung Association / SLA grants**

- J.-D. Aubert (Lausanne, CH)
- C. Barazzone (Geneva, CH)
- M. Brutsche (St. Gallen, CH)

15:45 - 15:55  
Effects of cigarette smoke, pneumococcus and emphysema
- C. Benarafa (Bern, CH)

15:55 - 16:05  
Obstructive Sleep Apnoe in Ehlers-Danlos
- M. Kohler (Zurich, CH)

16:05 - 16:15  
Azithromycin for immunomodulatory treatment of idiopathic pulmonary fibrosis
- M. Funke-Chambour (Bern, CH)

16:15 - 16:25  
Glycosaminoglycans as systemic markers for acute exacerbations in chronic obstructive pulmonary disease
- D. Stolz (Basel, CH)

16:25 - 16:35  
Congenital Cystic Adenomatoid Malformations a translational study
- I. Ruchonnet-Métrailer (Geneva, CH)

16:35 - 16:45  
Natural history of lung cancer and Cost-effectiveness of screening
- M. Puhan (Zurich, CH)

Satellite Symposium, Montreal

17:00 - 18:00  
**Satellite Symposium 3 - Transforming medical practice: new approaches to the treatment of severe asthma**

Supported by AstraZeneca

- L. Nicod (Lausanne, CH)
Scientific Programme

17:00 - 17:30  75  Biologics- Are they all the same?
R. Louis (Liege, BE)

17:30 - 18:00  76  The right medicine for the right patient
M. Tamm (Basel, CH)

Satellite Symposium, Singapore

17:00 - 18:00  Satellite Symposium 4 - How to manage severe emphysema patients? New Clinical Evidence and Recommendations.
Supported by Pulmonx
A. Valipour (Vienna, AT)

17:00 - 17:20  78  Latest Clinical Data on Endobronchial Valves
K. Klooster (Groningen, NL)

17:20 - 17:40  79  Best Practices for Patient Selection and Treatment
A. Valipour (Vienna, AT)

17:40 - 18:00  80  Review of clinical cases
D. Franzen (Zurich, CH)

Satellite Symposium, Sydney

17:00 - 18:00  Satellite Symposium 5 - Bronchiectasis and Alpha-1 Antitrypsin deficiency: two neglected diseases revisited
Supported by GRIFOLS / Vifor
S. Ott (Bern, CH)

17:00 - 17:30  81  New evidence from European registries on diagnosis and management of NCFBE
J. Rademacher (Hannover, DE)

17:30 - 18:00  82  Personalized Medicine in AATD in the view of current guidelines
R. Koczulla (Marburg, DE)

Public Event / Publikumsveranstaltung, Sydney

19:00 - 20:15  Public Event of the Swiss Lung Association: Sleep & OSAS
Thursday, 08 June 2017

08:15 - 09:15

Hands-on-Workshop: Lung function, Darwin

**Hands-on-Workshop 1: Bodyplethysmography**

Background and purpose, theory, equipment and measurement technique, measurement of Resistance, FRC, ERV and VC using body plethysmography and spirometry, quality control, reference values. Measurement of a proband.

Participation is limited to 12 delegates

P.-O. Bridevaux (Hôpital du Valais, Sion, CH)

08:15 - 08:25

Bodyplethysmography

08:15 - 09:15

Hands-on-Workshop: Lung function, Lima

**Hands-on-Workshop 3: CPET**

Background and purpose, theory, equipment and measurement technique, measurement and calculations of values, quality control, reference values and 9-field-panel of Wasserman. Measurement of a healthy proband. Participation is limited to 12 delegates

K. Bloch (Zurich, CH)

08:15 - 08:25

CPET

09:15 - 10:30

Session 13: GLI reference values: how they change lung function practice

X. Baur (Berlin, DE)
J. Kirkby (Sheffield, GB)

09:15 - 09:33

The history of GLI spirometry values

S. Stanojevic (Toronto, CA)

09:33 - 09:51

The impact of ethnicity on lung function

J. Kirkby (Sheffield, GB)

09:51 - 10:09

Current reference equations for lung function. How do they compare to GLI in daily life?

P.-O. Bridevaux (Hôpital du Valais, Sion, CH)

10:09 - 10:27

Why we should implement the new GLI values

X. Baur (Berlin, DE)
Scientific Programme

Parallel Session, Singapore

09:15 - 10:30  
**Session 14: Mycobacteria, fungi and opportunistic infections the susceptible host**

S. Ott (Bern, CH)  
G. Sotgiu (Sassari, IT)

09:15 - 09:40  95  
**Atypical mycobacteriosis**  
R. Wallace (Tyler, US)

09:40 - 10:05  96  
**Pulmonary complications in the hematologic patient**  
M. Tamm (Basel, CH)

10:05 - 10:30  97  
**Chronic Aspergillus Infection**  
D. Stevens (Stanford, US)

Parallel Session, Sydney

09:15 - 10:30  
**Session 16: Characterising lung cancer beyond imaging**

This session will be recorded and made available as webcast on the congress website and on the Novartis website "Vivinda TV" after the congress.

J. Flandes (Madrid, ES)  
P. Gasche-Soccal (Geneva, CH)

09:15 - 09:33  102  
**New classification of lung cancer**  
L. Bubendorf (Basel, CH)

09:33 - 09:51  103  
**Molecular biomarkers for lung cancer detection**  
A. Spira (Boston, US)

09:51 - 10:09  104  
**EBUS for molecular analysis - you just can't call it lung cancer anymore**  
G. Silvestri (Charleston, US)

10:09 - 10:27  105  
**Re-biopsy in NSCLC - when and how?**  
S. Rothschild (Basel, CH)

Parallel Session, Samarkand

09:15 - 10:30  
**Session 15: What is new in... State-of-the-art updates**

M. Brutsche (St. Gallen, CH)  
P. Laveneziana (Paris, FR)

09:15 - 09:33  98  
**Pulmonary embolism**  
D. Jimenez (Madrid, ES)

09:33 - 09:51  99  
**Sarcoidosis**  
J. Müller-Querheim (Freiburg, DE)

09:51 - 10:09  100  
**Air pollution**  
N. Probst-Hensch (Basel, CH)
Scientific Programme

10:09 - 10:27  101  Physical activity in lung disease
A. Schmidt-Trucksäss (Basel, CH)

Parallel Session, Montreal

11:00 - 12:15  Session 17: Free Communications - COPD
M. Cazzola (Rome, IT)
R. Irwin (Worcester, US)

106  Treatment of COPD exacerbation in Switzerland - results and recommendations of the European COPD Audit
M. Buess (University Hospital Basel, Basel, CH)

107  Which prognostic score to use in clinical COPD practise? An answer merging the assessment of prognostic properties and of clinical applicability
M. Puhan (Zurich, CH)

108  Laryngopharyngeal reflux in chronic obstructive lung disease - a multicenter study
J.C. Sanchez Perez (Universitätsspital Basel, Basel, CH)

109  Occupational exposure and the risk of chronic obstructive lung disease and mortality - A Swiss large-scale cohort study
A. Strassmann (University of Zurich, Zurich, CH)

110  On-line breath analysis with secondary electrospray ionization discriminates between COPD patients with and without frequent exacerbations
M.T. Gaugg (ETH Zürich, Zürich, CH)

Parallel Session, Singapore

11:00 - 12:15  Session 18: Free Communications - Sleep and breathing
R. Heinzer (Lausanne, CH)
O. Schoch (St. Gallen, CH)

111  Can early introduction of specialized palliative care limit intensive care, emergency and hospital admissions in patients with severe and very severe COPD? A pilot randomized study
J.-P. Janssens (Geneva University Hospitals, Geneva, CH)

C. Cantero (Groupement Hospitalier de l'Ouest Lémanique, Rolle, CH)

113  Is obstructive sleep apnea (OSA) a risk factor for the progression of thoracic aortic aneurysm (TAA)?
P. Rejmer (University Hospital Zurch, Zurich, CH)
114 Telemetrically triggered interventions in the first month of CPAP: 6-months results of a prospective, randomized controlled trial
O. Schoch (St. Gallen, CH)

115 Home-based non attended respiratory polygraphy in children: feasibility and accuracy for interpretation
R. Corbelli (University Hospital Geneva, Geneva, CH)

Parallel Session, Sydney
11:00 - 12:15
Session 19: Free Communications - Interstitial lung disease, translational research and pulmonary hypertension
M. Funke-Chambour (Bern, CH)
H. Olschewski (Graz, AT)

116 Multicenter, observational screening survey for the detection of chronic thromboembolic pulmonary hypertension following pulmonary embolism
N. Coquoz (Lausanne University Hospital, Lausanne, CH)

117 Serum levels of glycosaminoglycans are altered during acute exacerbations in chronic obstructive pulmonary disease
E. Papakonstantinou (University Hospital Basel, Basel, CH)

118 Lung-derived mesenchymal stem cells exert anti-fibrotic effects in vitro
K.E. Hostettler (University Hospital Basel, Basel, CH)

119 Exhaled breath analysis by real-time mass spectrometry in patients with pulmonary fibrosis
P. Sinues (ETH Zurich, Zurich, CH)

120 Teleradiology in interstitial lung disease: first experiences
K.E. Hostettler (University Hospital Basel, Basel, CH)

Parallel Session, Samarkand
11:00 - 12:15
Session 20: Free Communications - Lung cancer and thoracic surgery
P. Gasche-Soccal (Geneva, CH)
H.-B. Ris (CH)

121 Correlation between diversity of pulmonary diagnoses and distance to tertiary lung centers in Switzerland
A.-L. Walter (Cantonal Hospital of St. Gallen, St. Gallen, CH)

122 Clinical and oncological safety of 129 pulmonary segmentectomies by VATS
E. Abdelnour-Berchtold (CHUV, Lausanne, CH)
Scientific Programme

123 Utility of rapid on-site cytologic evaluation during EBUS-TBNA in malignant and non malignant disease
P. Gianella (Geneva University Hospitals, Geneva, CH)

124 Plasma thioredoxin reductase 1 as a diagnostic marker for non-small cell lung cancer
X.-Z. Kang (Peking University, Beijing, CN)

125 Outcome of patients with lung re-transplantation requiring preoperative extracorporeal membrane oxygenation
E. Abdelnour-Berchtold (CHUV, Lausanne, CH)

11:00 - 13:00 General Assembly of the SGPP

Poster Walk, Poster Exhibition - Foyer Level 2

Poster Walk 1: Airway disease I

T. Rothe (Davos, CH)
C. von Garnier (Berne, CH)

P126 Longitudinal change of COPD assessment test (CAT) in a telehealthcare cohort is associated with exacerbation risk
F. Rassouli (Kantonsspital St. Gallen, St. Gallen, CH)

P127 Asthma rehabilitation at high vs. low altitude: randomized controlled parallel-group trial
S. Saxer (University Hospital Zurich, Zürich, CH)

P128 Prevalence and risk factors for bronchiectasis in adult patients-A single center experience from United Arab Emirates
I. Saleem (Zayed Military Hospital, Abu Dhabi, AE)

P129 Overview of the inpatient management of acute exacerbations of COPD - A case-series
P.-O. Bridevaux (Hôpital du Valais, Sion, CH)

P130 Serum albumin is an independent predictor for respiratory hospitalization in patients with non-cystic fibrosis bronchiectasis
S.J. Lee (Gyeongsang National University Hospital, Jinju, KR)

P131 Prevalence of coronary artery diseases among COPD patients with more symptoms and low risk of exacerbation (GOLD B) in Ramathibodi hospital
T. Kawamatawong (Ramathibodi Hospital, Bangkok, TH)

P132 Recurrent pulmonary infections in a patient with tracheobronchopathia osteochondroplastica
J.R. Go (University of Hawaii John A. Burns School of Medicine, Honolulu, US)

P133 The correlation between oral health status and COPD exacerbations
D.A. Todea (Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, RO)
Scientific Programme

P134 Inclusion of patients with severe or very severe COPD in a randomised controlled trial on early specialised palliative care: a difficult challenge
J.-P. Janssens (Geneva University Hospitals, Geneva, CH)

P135 Right heart function and pulmonary pressure in asthma patients during 17 days at high-altitude
P.R. Bader (University Hospital Zurich, Zürich, CH)

P136 Pneumonitis and reactive airways dysfunction syndrome with persistent airway obstruction due to inhalation of industrial disinfectant: a case report.
S.Y. Chew (Division of Medicine, Singapore General Hospital, Singapore, SG)

P138 The aspect of GERD in the lung diseases with non-cystic fibrosis bronchiectasis
G. Capova (Hochgebirgsklinik, Davos, CH)

P139 One lung to live: a case of unilateral pulmonary artery agenesis
J. Patel (Kern Medical, Bakersfield, US)

Poster Walk, Poster Exhibition - Foyer Level 2

Poster Walk 2: Airway disease II

L. Nicod (Lausanne, CH)
M. Brutschen (St. Gallen, CH)

P140 Is it really Asthma? - appropriate assessment and testing is important for accurate diagnosis.
I. Saleem (Zayed Military Hospital, Abu Dhabi, AE)

P141 Multiple breath nitrogen washout and methacholine challenge test in patients with clinical suspicion of asthma and normal lung function
A. Siebeneichler (University Hospital Basel, Basel, CH)

P142 IFN3 polymorphisms and circulating levels are associated with COPD severity and outcomes
D.M. Schumann (University Hospital Basel, Basel, CH)

P143 Collagen degradation and formation markers in stable and exacerbated COPD
D.M. Schumann (University Hospital Basel, Basel, CH)

P145 Modeling of oxygen recovery after 6-min walk tests in COPD
F. Baty (Cantonal Hospital of St. Gallen, St. Gallen, CH)

P146 The patients with acute exacerbation of COPD maybe benefit from autotitrating EPAP during noninvasive ventilation: a prospective study
B. Han (PLA Rocket General Hospital, Beijing, CN)

P147 Is a questionnaire suitable to assess physical activity and its changes in COPD?
C. Clarenbach (University Hospital Zurich, Zurich, CH)

P148 Bacteria profile of acute exacerbations of chronic obstructive pulmonary disease in Singapore
P.Y. Tiew (Singapore General Hospital, Singapore, SG)
Scientific Programme

P149  Targeted on-line breath analysis discriminates COPD patients vs. healthy controls and subjects suffering from asthma
Y. Nussbaumer-Ochsner (University Hospital of Zurich, Zurich, CH)

P150  Insulin-like growth factor 1, leptin and adiponectin in patients with cystic fibrosis
M. Schuurmans (Zurich, CH)

P151  Endothelial dysfunction, disease severity and outcome in moderate to severe COPD
D.M. Schumann (University Hospital Basel, Basel, CH)

P152  Diagnostic discrepancies between rapid and standard polymerase chain reaction laboratory tests for influenza virus detection in nasopharyngeal swabs from symptomatic lung transplant recipients
M. Schuurmans (Zurich, CH)

P153  Active and second hand maternal smoking during pregnancy in Greece
A. Diamanti (Department of Midwifery, TEI, Athens, Greece, Athens, GR)

Poster Walk, Poster Exhibition - Foyer Level 2

Poster Walk 3: Sleep/Breathing

K. Bloch (Zurich, CH)
D. Adler (Geneva, CH)

P154  Effect of CPAP treatment for obstructive sleep apnea on long-term functional outcome in patients with ischemic stroke/TIA - A randomized controlled interventional trial (SAS-Care-2 Study)
S. Ott (Bern, CH)

P155  The effect of continuous positive airway pressure in atrial fibrillation after ablation and cardioversion
N. Srivali (Mayo Clinic, Rochester, US)

P156  Risk of cardiac arrhythmias in lowlanders with COPD travelling to high altitude. Randomized trial of nocturnal oxygen therapy
M. Bisang (University Hospital Zurich, Zurich, CH)

P157  Effect of repeated altitude exposure on nocturnal breathing disturbances in lowlanders.
M. Furian (University Hospital Zurich, Zurich, CH)

P158  CPAP compliance after a 3 month trial of interface selection
R.Y. Soh (Singapore General Hospital, Singapore, SG)

P159  Effects of subacute hypobaric hypoxia on human respiratory muscle function and diaphragm morphology
J. Pichler Hefii (Inselspital, University Hospital Bern, Bern, CH)

P160  Agreement between mouth maximal inspiratory pressure and sniff nasal inspiratory pressure in patients with amyotrophic lateral sclerosis and correlation with anthropometric measurements
J.-P. Janssens (Geneva University Hospitals, Geneva, CH)
Obstructive sleep apnoea and quality of life in Fabry disease: a parallel cohort study
D. Franzen (Zurich, CH)

Effect of treatment of central sleep apnoea/cheyne stokes respiration on left ventricular ejection fraction in heart failure - a network meta-analysis.
E.I. Schwarz (University Hospital of Zurich, Zürich, CH)

P. Pasquina (Geneva University Hospitals, Geneva, CH)

Nocturnal breathing in adult obese subjects with and without Prader-Willi syndrome
P. Fanari (Istituto Auxologico Italiano, Ospedale San giuseppe, Oggebbio (VB), IT)

Chest-MRI under non invasive high frequency ventilation: a new promising technique
A. Lovis (Lausanne, CH)

Initiative to improve outcomes through the use of an adult protocol for high-flow nasal cannula
T. Dempsey (University of California-Davis, Sacramento, US)

Development and first validation of a simple tool for clinical assessment of patients treated with home NIV: The S3-NIV questionnaire
D. Adler (Geneva, CH)

Agreement between sniff nasal inspiratory pressure and mouth maximal inspiratory pressure in patients surviving severe acute hypercapnic respiratory failure in the ICU
N. Glatz (Hôpitaux Universitaires de Genève, Genève, CH)

A. Kubbara (Univ of Toledo Medical Center, Toledo, US)

Positional central sleep apnea after single-lung transplantation - a case report
A. Schertel (University Hospital and University of Bern, Bern, CH)

Predicting quality adjusted life years using St. George respiratory results in patients with severe emphysema
R. Evans (ICON Health Economics & Epidemiology, Oxford, GB)

Qualitative analysis of pulmonary perfusion changes assessed by dual-energy computed-tomography after endoscopic lung volume reduction by coils
J. Plojoux (Geneva, CH)

Indications and complications of flexible bronchoscopy in very elderly patients
V. Clérigo (Centro Hospitalar Lisboa Norte, Lisbon, PT)
P174 The bronchial vacuum: a directional suction catheter that can access right or left bronchi consistently.
J. Roberts (Patient Centered Medical, Brentwood, US)

P175 Endobronchial coil therapy: first results from the swiss registry
P.M. Soccal (Geneva University Hospitals, Genève, CH)

P176 Case report of a tracheo-mediastinal fistula after radio-therapy
G. Berra (Geneva University Hospitals, Geneva, CH)

P177 A rare case of fentanyl-induced chest wall rigidity syndrome during routine bronchoscopy
C.K. Phua (Tan Tock Seng Hospital, Singapore, SG)

P178 Smoking history as a risk factor for atrial fibrillation following robotic-assisted video-thoracoscopic pulmonary lobectomy
J. Glover (University of South Florida Health Morsani College of Medicine, Tampa, US)

P179 Outcomes for right versus left lung malignancies after robotic-assisted pulmonary lobectomy
A. Groshev (University of South Florida Health Morsani College of Medicine, Tampa, US)

P180 Bronchopulmonary sequestration in adults - a Croatian single institution experience.
K.B. Sreter (University Hospital Centre ‘Sestre Milosrdnice’, Zagreb, HR)

P181 Acute right ventricular and pericardial wall perforation after a permanent endocardial pacemaker implantation
I. Salazar Hernandez (Hospital General de México Eduardo Liceaga, Mexico City, MX)

P182 A preoperative nomogram for tumor regression grade following induction chemotherapy for esophageal squamous cell carcinoma
X.-Z. Kang (Peking University, Beijing, CN)

P183 Histiocytic sarcoma of interdigitating reticular cells in the mediastinum - case report
A. Miotto (Hospital Sancta Maggiore, Sao Paulo, BR)

P184 Rare localization of distant metastasized Evans tumor in the chest cavity
L.C. Guglielmetti (University Hospital Zurich, Zurich, CH)

P185 Concomittant intrathoracic extrapulmonal and cervical hydatid cyst- 10 year follow-up
L.C. Guglielmetti (University Hospital Zurich, Zurich, CH)

P186 Adenoid cystic carcinoma of the distal trachea: a case report
Z. Djakovic (University Hospital Center Zagreb, University Clinic for Thoracic Surgery Jordanovac, Zagreb, HR)

P187 Diabetes predisposes patients to atrial fibrillation after robotic-assisted video-thoracoscopic pulmonary lobectomy
S. Reynolds (University of South Florida Health Morsani College of Medicine, Tampa, US)

P188 Effect of age on risk for atrial fibrillation following robotic-assisted video-thoracoscopic pulmonary lobectomy
J. Glover (University of South Florida Health Morsani College of Medicine, Tampa, US)
Scientific Programme

P189  Perioperative outcomes after robotic-assisted pulmonary lobectomy for upper versus lower lobe lung malignancies  
A. Groshev (University of South Florida Health Morsani College of Medicine, Tampa, US)

Poster Walk, Poster Exhibition - Foyer Level 2

Poster Walk 5: Epidemiology/Rehabilitation

J. Leuppi (Liestal, CH)  
M. Pons (Lugano, CH)

P190  Prevalence of abnormal spirometry in the general population of Lausanne according to GLI 2012. The PneumoLaus study.  
A. Lenoir (Centre Hospitalier Universitaire Vaudois, Lausanne, CH)

P191  Rehabilitation in elderly females with osteoporosis and impairment in pulmonary function  
P. Postolache (University of Medicine and Pharmacy Iasi, IASI, RO)

P192  An eighth week pulmonary rehabilitation in patients with non-cystic fibrosis bronchiectasis - observational study  
P. Postolache (University of Medicine and Pharmacy Iasi, IASI, RO)

P193  The introduction of step counters into a cardiopulmonary rehabilitation. A feasibility study with descriptive and statistical evaluation.  
G. Büsching (Barmelweid, CH)

P194  Chronic obstructive pulmonary disease hospitalizations and emergency department visits among queen Emma clinic patients: a quality improvement initiative  
J.R. Go (University of Hawaii John A. Burns School of Medicine, Honolulu, US)

P195  Correlations between smoking prevalence and the amount of CO at foster care teenagers  
D.A. Todea (Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, RO)

P196  Development of an internet portal on COPD in Portuguese  
J. Cravo (Centro Hospitalar e Universitário de Coimbra, Coimbra, PT)

P201  Race as a factor of providing care  
J. Varon (Dorrington Medical Associates, Houston, US)

P202  Does religion affect the care given by providers of sexual offender patients?  
J. Varon (Dorrington Medical Associates, Houston, US)

Poster Walk, Poster Exhibition - Foyer Level 2

Poster Walk 6: Basic Science/Pulmonary hypertension

M. Roth (Basel, CH)  
S. Ulrich (Zurich, CH)

P204  Autophagic dysfunction is improved by the administration of the endoplasmic reticulum stress inhibitor trimethylamine-N-oxide in a murine model of neutrophilic asthma  
B. Zhou (The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, CN)
Scientific Programme

P205  Real-time exhaled breath analysis identifies altered metabolic signature in cystic fibrosis  
F. Singer (University Children’s Hospital Zurich, Zurich, CH)

P206  Read-through fusion transcripts in lung cancer  
F. Baty (Cantonal Hospital of St. Gallen, St. Gallen, CH)

P207  Multi-walled carbon nanotubes exposure in healthy and chronic obstructive pulmonary disease  
S.M. Beyeler (University of Bern, Bern, CH)

P208  Nicotine exposure during gestation and lactation affects cell proliferation and lung volume during lung development in mice  
S. Blaskovic (University of Geneva, CMU, Genève, CH)

P209  Effect of normobaric hypoxia on pulmonary hemodynamics in patients with precapillary pulmonary hypertension  
A. Groth (University Hospital Zurich, Zürich, CH)

P210  Modern management of portopulmonary hypertension in children: experience of an expert center  
F. Lador (Geneva, CH)

P211  Pulmonary perfusion changes after balloon pulmonary angioplasty (BPA) for chronic thromboembolic pulmonary hypertension (CTEPH)  
F. Lador (Geneva, CH)

P212  MRI derived global right ventricle diastolic strains correlate with mPAP in CTEPH patients  
F. Lador (Geneva, CH)

P213  Severity of pulmonary hypertension correlates with patients’ daily physical activity  
S. Saxer (University Hospital Zurich, Zürich, CH)

P214  Right-to-left shunt in patients with COPD at high altitude - a randomized, placebo-controlled trial with dexamethasone  
M. Lichtblau (University Hospital Zurich, Zürich, CH)

P215  Effect of repeated exposure to very high altitude on lung function in healthy lowlanders.  
M. Furian (University Hospital Zurich, Zurich, CH)

P216  Real-life data on the medical therapy of pulmonary arterial and chronic thromboembolic pulmonary hypertension  
P. Bartenstein (University Hospital Zurich, Zurich, CH)

P217  Extravascular lung water in healthy lowlanders during repeated high altitude exposure  
P.R. Bader (University Hospital Zurich, Zürich, CH)

P218  Assessment of mean pulmonary artery pressure with 4D flow MRI  
F. Lador (Geneva, CH)
Poster Walk, Poster Exhibition - Foyer Level 2

**Poster Walk 7: Infection/Lung Cancer**

J.-D. Aubert (Lausanne, CH)
S. Ott (Bern, CH)

**P219**
Screening for active tuberculosis in an urban shelter for homeless in Switzerland: a prospective study
J.-P. Janssens (Geneva University Hospitals, Geneva, CH)

**P220**
So you have a typical pneumonia... with MAC?
S. Saha (Michigan State University/St. John Providence Hospital, Southfield, US)

**P221**
Time to diagnosis in patients treated for tuberculosis in the Geneva area: a pilot study
J.-P. Janssens (Geneva University Hospitals, Geneva, CH)

**P222**
Practices regarding isolation for non-MDR pulmonary tuberculosis: a TB-NET survey of specialists from 44 countries
J.-P. Janssens (Geneva University Hospitals, Geneva, CH)

**P223**
Tuberculosis. Medico-social approach in canton of Vaud, Switzerland
J. Mazza-Stalder (Lausanne University Hospital, Lausanne, CH)

**P224**
Comparison of clinical outcomes and radiographic characteristics between smear negative (clinically diagnosed) and smear positive (bacteriologically diagnosed) pulmonary tuberculosis with category I (2HRZE/4HR) treatment at Cagayan valley medical center: a pilot study
R. Busway (Cagayan Valley Medical Center, Tuguegarao City, PH)

**P225**
Evaluation of antimicrobial therapy in the ICU - fluid overload or pneumonia?
U. Mbadugha (Corpus Christi Medical Center, Corpus Christi, US)

**P226**
Systemic lupus erythematos with apparently acute onset with respiratory failure caused by mixed infection (klebsiella and pneumocystis jiroveci)
G. Jimborean (University of Medicine and Pharmacy Tg. Mures, Targu Mures, RO)

**P227**
Comparison of clinical profile of patients with ALK-positive and EGFR-positive non-small cell lung adenocarcinoma in an Indian population
A.M. Bamania (All India Institute of Medical Sciences, New Delhi, IN)

**P228**
Systematic review of lung cancer screening trials with low dose computed-tomography: 2017 update
T. Dao (Touro College of Osteopathic Medicine, Orange Regional Medical Center, Middletown, US)

**P229**
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) - a rare syndrome masquerading as metastatic carcinoma
S. Hameed (Montefiore Medical Center, New York, US)

**P230**
Decreasing hospital stay by adopting the short term hospitalization system for lung cancer diagnosis
C. Leem (Seoul National University Bundang Hospital, Respiratory Center, Seongnam, KR)
Scientific Programme

Poster Walk, Poster Exhibition - Foyer Level 2

**Poster Walk 8: Interstitial lung disease/ICU/Pediatrics**

T. Geiser (Berne, CH)
J. Hammer (Basel, CH)
C. Lambers (Vienna, AT)

**P231**
Respiratory breathing patterns and cough in idiopathic pulmonary fibrosis: awake, asleep and over time
A. Schertel (University Hospital and University of Bern, Bern, CH)

**P232**
Prevalence of lung cancer in combined pulmonary fibrosis and emphysema: a single center experience
F. Nasim (Mayo Clinic, Rochester, US)

**P233**
A case report: Interstitial lung disease in Vietnamese children with SFTPC, SFTPB gene mutation
L. Diem (Children's Hospital Number 1, Ho Chi Minh, VN)

**P234**
Clinical practice of idiopathic pulmonary fibrosis patients in a Swiss ILD reference center
M. Funke (University Bern, Bern, CH)

**P235**
Serum VEGF-D level as a diagnostic biomarker of lymphangioleiomyomatosis in clinical practice
C. Daccord (Lausanne University Hospital, Lausanne, CH)

**P236**
Thinking of lymphoma? But what about abdominal sarcoidosis?
S. Saha (Michigan State University/St. John Providence Hospital, Southfield, US)

**P237**
Pleuroparenchymal fibroelastosis in a previously healthy woman
J. Cravo (Centro Hospitalar e Universitário de Coimbra, Coimbra, PT)

**P238**
Preserved lung parenchyma of idiopathic pulmonary fibrosis patients has increased expiratory CT densities- a sign for increased alveolar collapsibility?
M. Funke (University Bern, Bern, CH)

**P239**
Diagnostic potential of MMP-1 and SP-A as biomarkers to distinguish chronic hypersensitivity pneumonitis from Idiopathic pulmonary fibrosis
I. Buendía-Roldán (Instituto Nacional de Enfermedades Respiratorias, Mexico, MX)

**P240**
Risk of pneumothorax due to air travel in pulmonary lymphangioleiomyomatosis
C. Daccord (Lausanne University Hospital, Lausanne, CH)

**P241**
Validation of APPS tool to predict mortality in moderate and severe acute respiratory distress syndrome
V. Jayaschandran (William Beaumont Hospital, Royal Oak, US)

**P242**
Concurrent validity of sequential organ failure assessment versus systemic inflammatory response syndrome score for patients in the intensive care unit.
B. Donald (Corpus Christi Medical Center, Corpus Christi, US)

**P243**
Reliability and utility of the Ramsay sedation scale for dosing sedatives in critically ill intubated patients
H. Deol (Corpus Christi Medical Center, Corpus Christi, US)
Scientific Programme

P244  Serum YKL-40 levels may help distinguish exacerbation of post-infectious bronchiolitis obliterans from acute bronchiolitis in young children
H.L. Chung (Catholic University of Daegu, Daegu, KR)

P245  Six minute walk test in children six to eighteen years old with bronchial asthma
C. Capili (Philippine Children's Medical Center, Quezon City, PH)

P246  Exhalomics SESI-MS feasibility study with infants and young children for early detection of cystic fibrosis inflammation and infection
T. Bruderer (ETH Zürich, Zürich, CH)

Parallel Session, Montreal
14:00 - 15:15  Session 21: Options for treating pulmonary hypertension today
F. Lador (Geneva, CH)
I. Schmitt-Opitz (Zurich, CH)
14:00 - 14:18  247  How to start: mono vs. dual therapy
O. Sitbon (Paris, FR)
14:18 - 14:36  248  Anticoagulation: friend or foe?
H. Olschewski (Graz, AT)
14:36 - 14:54  249  Treatment of PAH in lung disease
S. Ulrich (Zurich, CH)
14:54 - 15:12  250  Pulmonary endarterectomy vs. balloon pulmonary angioplasty in CTEPH
C. Wiedenroth (Bad Nauheim, DE)

Parallel Session, Singapore
14:00 - 15:15  Session 22: Early life influences on adult lung disease
C. Barazzone (Geneva, CH)
C. Kuehni (Bern, CH)
14:00 - 14:18  251  Lessons learned from farming studies
E. von Mutius (Munich, DE)
14:18 - 14:36  252  Microbiome: Lessons learned from animal models
B. Marsland (Lausanne, CH)
14:36 - 14:54  253  The link between early life and COPD development
F.D. Martinez (Tucson, US)
14:54 - 15:12  254  Can we influence disease trajectories and lung function development?
U. Frey (Basel, CH)
### Parallel Session, Sydney

#### 14:00 - 15:15

**Session 23: Understanding COPD treatment strategies**

This session will be recorded and made available as webcast on the congress website and on the Novartis website “Vivinda TV” after the congress.

- **14:00 - 14:18**
  - 255
  - **Mechanisms of acute exacerbations of COPD**
  - P. Barnes (London, GB)

- **14:18 - 14:36**
  - 256
  - **Treating the COPD patient with frequent exacerbation**
  - R. Koczulla (Marburg, DE)

- **14:36 - 14:54**
  - 257
  - **ICS in COPD: less is more**
  - H. Magnussen (Hamburg, DE)

- **14:54 - 15:12**
  - 258
  - **ICS in COPD: more is more**
  - M. Dransfield (Birmingham, US)

### Parallel Session, Samarkand

#### 14:00 - 15:15

**Session 24: Interstitial lung disease: The essentials and more**

This session is supported by GlaxoSmithKline

- **14:00 - 14:18**
  - 259
  - **Imaging in ILD**
  - J. Bremerich (Basel, CH)

- **14:18 - 14:36**
  - 260
  - **Hypersensitivity pneumonia/chronic NSIP**
  - L. Nicod (Lausanne, CH)

- **14:36 - 14:54**
  - 261
  - **Lymphangioleiomyomatosis/Histiocytosis X**
  - S. Levine (San Antonio, US)

- **14:54 - 15:12**
  - 262
  - **Drug-induced or disease associated ILD in collagen vascular disease**
  - P. Camus (Dijon, FR)
Hands-on Course, Darwin

15:00 - 16:00 Hands-on-Workshop 5: Endoscopic lung volume reduction with valves

non-CME accredited company supported hands-on workshop by PulmonX. The workshop is designed to allow participants to gain practical skills in the placement of endobronchial valves in pig lung models. Besides, attendants will learn how to select the right patients by identifying collateral ventilation with the StratX software and the Chartis Assessment tool. Participation is limited to 12 delegates.

A. Valipour (Vienna, AT)

15:00 - 16:00 263 Endoscopic lung volume reduction with valves

Hands-on Course, Boston 3

15:00 - 16:00 Hands-on-Workshop 6: EBUS & peripheral procedures - enlarge your diagnostic area

non-CME accredited company supported hands-on workshop by Olympus. Participation is limited to 12 delegates.

K.-J. Franke (Hagen, DE)

15:00 - 16:00 264 EBUS & peripheral procedures - enlarge your diagnostic area

Hands-on Course, Lima

15:00 - 16:00 Hands-on-Workshop 9: ASV- and BiPAP-AVAPS therapy using telemonitoring

non-CME accredited company supported hands-on workshop by Philips. Update in complex ASV (Auto-Servo-Ventilation) and BiPAP-AVAPS (Average Volume Assured Pressure Support) therapy in combination with telemonitoring. Assessment and decision with a focus on the therapy efficiency to reach the highest value of patients compliance. In this context you will become acquainted with an innovative wireless titration module which allows you to get all data in one final report. Participation is limited to 12 delegates.

D. Puoti (Zofingen, CH)
T. Kunze (Hamburg, DE)

15:00 - 16:00 265 ASV- and BiPAP-AVAPS therapy using telemonitoring

Parallel Session, Montreal

15:45 - 16:45 Session 25: Treatment strategies for sleep apnea and COPD

R. Heinzer (Lausanne, CH)
J. Stradling (Oxford, GB)
### Scientific Programme

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:45 - 16:05</td>
<td>266</td>
<td>Treatment alternatives in obstructive sleep apnea</td>
<td>M. Kohler (Zurich, CH)</td>
</tr>
<tr>
<td>16:05 - 16:25</td>
<td>267</td>
<td>Surgery for sleep apnoe</td>
<td>J.T. Maurer (Mannheim, DE)</td>
</tr>
<tr>
<td>16:25 - 16:45</td>
<td>268</td>
<td>NIV in COPD</td>
<td>N. Hart (London, GB)</td>
</tr>
<tr>
<td>15:45 - 16:45</td>
<td></td>
<td>Parallel Session, Singapore</td>
<td></td>
</tr>
<tr>
<td>15:45 - 16:05</td>
<td></td>
<td>Session 26: Pushing the limits in lung transplantation</td>
<td>J.-D. Aubert (Lausanne, CH)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>M. Schuurmans (Zurich, CH)</td>
</tr>
<tr>
<td>15:45 - 16:05</td>
<td>269</td>
<td>30 years of experience with lung transplantation - where are we now?</td>
<td>T. Welte (Hannover, DE)</td>
</tr>
<tr>
<td>16:05 - 16:25</td>
<td>270</td>
<td>Borderline indication for LTx</td>
<td>S. Levine (San Antonio, US)</td>
</tr>
<tr>
<td>16:25 - 16:45</td>
<td>271</td>
<td>Management of long term complications</td>
<td>G. Verleden (Leuven, NL)</td>
</tr>
<tr>
<td>15:45 - 16:45</td>
<td></td>
<td>Parallel Session, Sydney</td>
<td></td>
</tr>
<tr>
<td>15:45 - 16:05</td>
<td></td>
<td>Session 27: Breathlessness explained</td>
<td>F. Michel (Luzern, CH)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>M. Dransfield (Birmingham, US)</td>
</tr>
<tr>
<td>15:45 - 16:05</td>
<td>272</td>
<td>Respiratory mechanics and dyspnoea</td>
<td>D. O’Donnell (Kingston, CA)</td>
</tr>
<tr>
<td>16:05 - 16:25</td>
<td>273</td>
<td>The prognostic role of CPET in pulmonary disease</td>
<td>P. Laveneziana (Paris, FR)</td>
</tr>
<tr>
<td>16:25 - 16:45</td>
<td>274</td>
<td>Inhaled medication - which device for which patient?</td>
<td>M. Cazzola (Rome, IT)</td>
</tr>
<tr>
<td>15:45 - 16:45</td>
<td></td>
<td>Parallel Session, Samarkand</td>
<td></td>
</tr>
<tr>
<td>15:45 - 16:05</td>
<td></td>
<td>Session 28: State-of-the-art asthma</td>
<td>T. Rothe (Davos, CH)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>F.D. Martinez (Tucson, US)</td>
</tr>
<tr>
<td>15:45 - 16:05</td>
<td>275</td>
<td>Importance of inflammatory phenotypes in asthma</td>
<td>R. Louis (Liege, BE)</td>
</tr>
</tbody>
</table>
## Scientific Programme

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:05 - 16:25</td>
<td>Is this really asthma?</td>
<td>J.C. Virchow (Rostock, DE)</td>
</tr>
<tr>
<td>16:25 - 16:45</td>
<td>Severe asthma - managing type 2 vs. non-type 2 asthma</td>
<td>M. Gaga (Athens, GR)</td>
</tr>
<tr>
<td>17:00 - 18:00</td>
<td>Satellite Symposium 6 - When CPAP isn’t enough - from ASV to AVAPS-AE</td>
<td>W. Randerath (CH)</td>
</tr>
<tr>
<td>17:00 - 17:15</td>
<td>Sleep and ventilation have a strong mutual relevance</td>
<td>W. Galetke (Köln, DE)</td>
</tr>
<tr>
<td>17:15 - 17:30</td>
<td>ASV - fields of treatment with patient cases</td>
<td>W. Randerath (CH)</td>
</tr>
<tr>
<td>17:30 - 17:45</td>
<td>Still ASV or better NIV - fields of treatment with patient cases</td>
<td>W. Randerath (CH)</td>
</tr>
<tr>
<td>17:45 - 18:00</td>
<td>AVAPS and AVAPS-AE - fields of treatment with patient cases</td>
<td>W. Galetke (Köln, DE)</td>
</tr>
<tr>
<td>18:00 - 19:00</td>
<td>General Assembly of the SGP</td>
<td></td>
</tr>
<tr>
<td>19:00 - 20:15</td>
<td>Public Event of the University Hospital Basel: Lung and sports</td>
<td></td>
</tr>
</tbody>
</table>
**Scientific Programme**

**Friday, 09 June 2017**

<table>
<thead>
<tr>
<th>Time</th>
<th>Section</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15 - 09:15</td>
<td>Hands-on Course, Kairo 1&amp;2</td>
<td>Hands-on-Workshop 8: Hands-on practice with PneumRx coils for the endoscopic treatment of severe emphysema. Non-CME accredited company supported hands-on workshop by PneumRx. Participation is limited to 12 delegates.</td>
</tr>
<tr>
<td>08:15 - 09:15</td>
<td>Hands-on practice with PneumRx coils for the endoscopic treatment of severe emphysema</td>
<td></td>
</tr>
<tr>
<td>08:15 - 09:15</td>
<td>Hands-on-Workshop: Lung function, Darwin</td>
<td>Hands-on-Workshop 1: Bodyplethysmography. Background and purpose, theory, equipment and measurement technique, measurement of Resistance, FRC, ERV and VC using body plethysmography and spirometry, quality control, reference values. Measurement of a proband. Participation is limited to 12 delegates.</td>
</tr>
<tr>
<td>08:15 - 09:15</td>
<td>Bodyplethysmography</td>
<td></td>
</tr>
<tr>
<td>08:15 - 09:15</td>
<td>Hands-on-Workshop: Physio, Boston 3</td>
<td>Hands-on-Workshop 4: Physiotherapy in lung diseases. Learn about physiotherapy techniques and assessments used in patients with lung diseases. This includes pulmonary rehabilitation in COPD, sputum mobilisation in Cystic Fibrosis, breathing techniques, such as pursed lip breathing in Asthma and bodypositioning for easier breathing. The Workshop is led by experienced physiotherapist. Attend to experience: •Hands-on experience in using various Positiv Expiratory Pressure (PEP)-Systems such as Flutter VRP1, Acapella, Pari PEP or RC-Cornet. •Learn about endurance and resistance training in pulmonary rehabilitation based on the latest research findings. •Try out a sit-to-stand test as an alternative assessment to a 6 MWT Target Audience Physicians and health-care professionals from pulmonary medicine are encouraged to attend. Participation is limited to 12 delegates.</td>
</tr>
<tr>
<td>08:15 - 09:15</td>
<td>Physiotherapy in lung diseases</td>
<td></td>
</tr>
</tbody>
</table>
### Scientific Programme

#### 08:15 - 09:15
**Hands-on-Workshop: Lung function, Lima**

#### 09:15 - 10:30
**Plenary Session 2: Keynote Lecture and Awards**

- **09:15 - 10:00**
  - **Keynote Lecture 2**
  - J. Herzog (Basel, CH)

- **10:00 - 10:25**
  - **Award Presentations**

- **10:25 - 10:30**
  - **Closing words**
  - D. Stolz (Basel, CH)

#### 10:45 - 12:00
**Session 32: Swiss Pulmonary Challenge**

- **10:45 - 12:00**
  - **Swiss Pulmonary Challenge**
  - K. Bloch (Zurich, CH)
  - T. Brack (Glarus, CH)

#### 11:00 - 12:00
**Session 29: Management of the pulmonary nodule - interactive case discussion**

- **11:00 - 11:20**
  - **Case 1**
  - P. Gasche-Soccal (Geneva, CH)

- **11:20 - 11:40**
  - **Case 2**
  - G. Silvestri (Charleston, US)

- **11:40 - 12:00**
  - **Case 3**
  - P. Chhajed (Mumbai, IN)
Scientific Programme

Parallel Session, Singapore

11:00 - 12:00  
Session 30: Clinical year in review

11:00 - 11:20  
Tuberculosis  
J.M. Porcel (Lleida, ES)

11:20 - 11:40  
Smoking and e-cigarette  
C. Clair (Lausanne, CH)

11:40 - 12:00  
Allergy  
J.C. Virchow (Rostock, DE)

Parallel Session, Samarkand

11:00 - 12:00  
Session 31: Sleep-disordered breathing: detect, evaluate and treat correctly

11:00 - 11:15  
Screening for sleep apnoe – does it make sense?  
R. Tamisier (Grenoble, FR)

11:15 - 11:30  
Phenoptyping obstructive sleep apnea  
M. Kohler (Zurich, CH)

11:30 - 11:45  
Pathophysiological effects of OSA  
J. Stradling (Oxford, GB)

11:45 - 12:00  
Which patients with sleep-disordered breathing should be treated?  
R. Heinzer (Lausanne, CH)

Parallel Session, Montreal

12:05 - 13:05  
Session 33: COPD

12:05 - 12:25  
COPD screening  
J. Soriano (Mallorca, ES)

12:25 - 12:45  
Dynamic lung hyperinflation in COPD  
P. Laveneziana (Paris, FR)

12:45 - 13:05  
When to treat alpha-1 antitrypsin deficiency?  
M. Kohler (Zurich, CH)
Parallel Session, Singapore

**Session 34: Approach to diseases of the pleura**

**12:05 - 13:05**

**12:05 - 12:25** 302  
*Treating bronchopleural fistula as a pneumologist*  
A. Valipour (Vienna, AT)

**12:25 - 12:45** 303  
*Chronic pleural effusion*  
J.M. Porcel (Lleida, ES)

**12:45 - 13:05** 304  
*Empyema treatment: tube vs. medical thoracoscopy vs. VATS/thoracotomy*  
L. Kern (St. Gallen, CH)

Parallel Session, Sydney

**Session 35: Progress in interstitial lung disease management**

**12:05 - 13:05**

**12:05 - 12:25** 305  
*Stem cells as a future therapy in ILD*  
T. Geiser (Bern, CH)

**12:25 - 12:45** 306  
*GERD and LPR in interstitial lung disease*  
R. Carbone (Genoa, IT)

**12:45 - 13:05** 307  
*Immunotherapy-associated pneumonitis*  
M. Brutsche (St. Gallen, CH)

Parallel Session, Samarkand

**Session 36: Pediatric Grand Rounds**

**12:05 - 13:05**

**12:05 - 12:20** 308  
*Non-allergic aspergillus bronchitis in CF*  
M. Hitzler (Zürich, CH)

**12:20 - 12:35** 309  
*Follicular bronchiolitis: a rare diagnosis of interstitial lung disease in children*  
I. Ruchonnet-Métrailler (Geneva, CH)
12:35 - 12:50  310  Abdominal pain and dyspnoea - not necessarily lower lobe pneumonia  
I. Maschler (St. Gallen, CH)

12:50 - 13:05  311  Progressive dyspnea in an adolescent girl  
M. Lurà (Luzern, CH)